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ABSTRACT: 
 
Smoking is an important risk factor for cardiovascular disease (CVD) morbidity and mortality. 
The impact of statin therapy on CVD risk by smoking status has not been fully investigated. 
Therefore we assessed the impact of statin therapy on CVD outcomes by smoking status through 
a systematic review of the literature and meta-analysis of available randomized controlled trials 
(RCTs). The literature search included EMBASE, ProQuest, CINAHL and PUBMED databases 
to 30 January 2016 to identify RCTs that investigated the effect of statin therapy on cumulative 
incidence of major CVD endpoints (e.g. non-fatal myocardial infarction, revascularization, 
unstable angina, and stroke). Relative risks (RR) ratios were calculated from the number of 
events in different treatment groups for both smokers and non-smokers. Finally 11 trials with 
89,604 individuals were included. The number of smokers and non-smokers in the statin groups 
of the analyzed studies was 8826 and 36,090, respectively. The RR for major CV events was 
0.73 (95% confidence interval [CI]: 0.67-0.81; p<0.001) in nonsmokers and 0.72 (95%CI: 0.64-
0.81; p<0.001) in smokers. Moderate to high heterogeneity was observed both in non-smokers 
(I2=77.1%, p<0.001) and in smokers (I2=51.6%, p=0.024) groups. Smokers seemed to benefit 
slightly more from statins than non-smokers according to the number needed to treat (NNT) 
analysis (23.5 vs 26.8) based on RRs applied to the control event rates. The number of avoided 
events per 1000 individuals was 42.5 (95%CI: 28.9-54.6) in smokers and 37.3 (95%CI: 27.2-
46.4) in non-smokers. In conclusion, this meta-analysis suggests that the effect of statins on 
CVD is similar for smokers and non-smokers, but in terms of NNTs and number of avoided 
events, smokers seem to benefit more although non-significantly. 
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BACKGROUND:  
Currently, smoking is a cause of 5 million premature deaths globally each year with 50% of 
smokers being middle age persons (1, 2). According to the World Health Organization (WHO) 
the deaths caused by smoking will increase to as many as 8 million persons/year (3). Cigarettes 
contain >5000 carcinogenic, toxic and mutagenic chemicals, stable and unstable free radicals, 
and reactive oxygen that substantially increase the morbidity and mortality from pulmonary 
disease and a wide array of cancers worldwide (4). Smoking, a preventable public health issue, 
also represents an important individual risk factor for cardiovascular disease (CVD) morbidity 
and mortality (5), additional to heritable and environmental risk factors, such as male gender, 
dyslipidemia, obesity, hypertension, diabetes, lack of physical activity, and inflammation (6). 
Transcriptomic studies have shown that smoking is responsible for changing gene expression in 
whole blood, circulating monocytes and lymphocytes in humans (6-8). A recent study on young, 
healthy intermittent smokers showed a rapid increase in the number of circulating endothelial 
progenitor cells and microparticles of leukocyte, platelet and endothelial origin even after 
smoking a single cigarette, suggesting a systemic cascade of vascular events that might promote 
mechanisms important in the development of atherosclerosis (9). 
Statins are commonly prescribed drugs (10) that are well tolerated and which effectively 
reduce the risk of CV events both in primary and secondary prevention (11, 12). They play a 
critical role in CVD patients, as they significantly lower the risk of acute myocardial infarction 
(AMI), stroke, cardiovascular revascularization, cardiac mortality and all-cause mortality (13, 
14). Importantly, these effects might be observed irrespective of whether low density lipoprotein 
cholesterol (LDL-C) goals are achieved (13, 14). Cigarette smoking was found, to diminish the 
beneficial effect of statins in some clinical trials (15), but the role of cigarette smoking in 
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modifying the effects of statin therapy is not well studied. Therefore, we aimed to assess the 
impact of statin therapy on CV outcomes by smoking status, through systematic reviews of the 
literature and meta-analysis of prospective controlled studies. 
 
METHODS 
We followed the guidelines of the 2009 preferred reporting items for systematic reviews and 
meta-analysis (PRISMA) statement (16). Due to the study design (meta-analysis) neither 
Institutional Review Board (IRB) approval, nor patient informed consent were needed or 
obtained. 
 
Search Strategy 
The literature search included EMBASE, ProQuest, CINAHL and PUBMED databases to 30 
January 2016 to identify primary or secondary prevention RCTs investigating the effect of statin 
therapy on cumulative incidence of major CVD endpoints (e.g. non-fatal myocardial infarction, 
CV revascularization, unstable angina, and stroke). Databases were searched using the following 
terms in titles and abstracts: ("atorvastatin" OR "simvastatin" OR "rosuvastatin" OR "fluvastatin" 
OR "pravastatin" OR "pitavastatin" OR "lovastatin" OR "cerivastatin" OR "statin therapy" OR 
“statins” OR "hydroxymethylglutaryl-CoA reductase inhibitors") AND "smoking" AND 
“randomized controlled trial”. Additional searches for potential trials included the references of 
review articles on that issue, and the abstracts from selected congresses: scientific sessions of the 
European Society of Cardiology (ESC), the American Heart Association (AHA), American 
College of Cardiology (ACC), European Society of Atherosclerosis (EAS) and National Lipid 
Association (NLA). The wild-card term ‘‘*’’ was used to increase the sensitivity of the search 
5 
	
strategy. The literature search was limited to articles published in English and to studies in 
humans. 
All paper abstracts were screened by two reviewers (SU and MCS) in an initial process to 
remove ineligible articles. The remaining articles were obtained in full-text and assessed again 
by the same two researchers who evaluated each article independently, carried out data 
extraction and quality assessment. Disagreements were resolved by discussion with a third party 
(MB). 
 
Study Selection 
The criteria for inclusion in this meta-analysis were: (i) randomized treatment allocation, (ii) 
a placebo arm, (iii) follow-up of at least 1 year, (iv) CV event as the primary or secondary 
endpoint, (v) ≥100 participants in the intervention group, (vi) results reported separately for 
smokers and non-smokers. 
Exclusion criteria were: (i) non-clinical studies, (ii) lack of a statin-free control group in the 
study design, and, (iii) lack of sufficient information on smoking status on baseline or during 
follow-up. 
 
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's 
name; 2) year of publication; 3) country were the study was performed; 4) study design; 5) 
number of participants in statin and control groups; 6) statin type; 7) statin intervention; 8) 
median follow-up; 9) age and gender of study participants; 10) data regarding CV events. If data 
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were presented separately for never-smokers and ex-smokers, these two categories were 
collapsed into a non-smoker category. 
Data extraction was performed independently by 2 reviewers (SU and MCS); disagreements 
were resolved by a third reviewer (MB). 
 
Quality assessment 
Assessment of risk of bias in the studies included in the analysis was performed 
systematically using the Cochrane quality assessment tool for RCTs (17). The Cochrane tool has 
7 criteria for quality assessment: random sequence generation (selection bias), allocation 
sequence concealment (selection bias), blinding of participants and personnel (performance 
bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), 
selective outcome reporting (reporting bias) and other potential sources of bias. The risk of bias 
in each study was judged to be low, high or unclear. 
Risk-of-bias assessment was performed independently by 2 reviewers (SU and MCS); 
disagreements were resolved by a third reviewer (MB). 
 
Statistical analyses 
Relative risks (RR) were calculated from the number of events in different treatment groups 
for smokers and for non-smokers in the included RCTs. We used the DerSimonian and Laird 
(18) random effects models as a primary method and the Mantel-Haenszel (MH) (19, 20) method 
as an alternative approach to calculate the pooled RR and 95% confidence intervals (CIs). 
DerSimonian and Laird method uses a simple random effects model allowing for treatment 
effects to vary across studies. It uses a simple non-iterative method to estimate the inter-study 
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treatment effect variance. The MH method uses a fixed-effect approach to meta-analysis. 
Heterogeneity among RRs was evaluated with the Higgins’ I2 statistic that describes the 
percentage of total variation among studies due to heterogeneity. The following categorization 
was used: 25% low, 50% moderate and 75% high heterogeneity (21). Galbraith plots, which are 
scatter plots for each z-statistic against the reciprocal value of the standard error, and also 
identify trials outside the pooled 95%CI estimate, were also depicted in order to assess 
heterogeneity (22). We explored differences in baseline risk and heterogeneity between studies 
by using l’Abbé plots (23). Meta-funnel plots were used to investigate possible publication bias 
(24). We investigated the influence of each study on the overall meta-analysis summary estimate 
(sensitivity analysis). In order to do the influence analysis in which the results are re-estimated 
omitting each study in turn (leave-one-out), we needed to derive the treatment effect estimate (in 
this case log risk ratio) and its standard error, for each study. We used the Harbord test – a 
modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. 
This test proposed by Harbord, Egger, and Sterne (25), is a modified version of the commonly 
used test of Egger et al.(26). It is based on the component statistics of the score test, namely, the 
efficient score, Z, and the score variance (Fisher’s information), V (27). 
We also calculated the number needed to treat (NNT) and the number of avoided events. 
NNT is the number of individuals required to experience the intervention in order to avoid one 
CV event. The NNT is equal to 1/(control group event rate - treatment group event rate). The 
number of avoided events per 1000 individuals is the difference between the two events rates 
multiplied by 1000.  
The optimum information size (OIS) was calculated for each analysis (28). It is defined as 
the minimum amount of information required to reach reliable conclusions in a meta-analysis. 
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Estimating the OIS may help to determine whether there is sufficient data to draw reliable 
conclusions. 
Data analysis was carried with STATA software (version 9.2, STATA Corporation, College 
Station, TX, USA) using the metan procedure. OIS was determined with the Trial Sequential 
Analysis (TSA) software downloaded at www.ctu.dk/tsa. 
 
RESULTS 
Search results and trial flow 
The search initially identified 2712 full text articles. After excluding duplicates, the titles 
and abstracts of 2612 papers were screened, from which 2571 papers were excluded. Among the 
remaining 41 full text articles assessed for eligibility, 30 studies were excluded for not having 
data results reported separately for smokers and non-smokers. After final assessment, 11 eligible 
RCTs achieved the inclusion criteria and were selected for the final meta-analysis (Figure 1). 
 
Characteristics of included studies 
Eleven trials with 89,604 individuals (44,916 in statin group and 44,688 controls) were 
included: the West of Scotland Coronary Prevention Study (WOSCOPS), the Cholesterol and 
Recurrent Events (CARE), the Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS), the Long-Term Intervention with Pravastatin in Ischaemic Disease 
(LIPID), the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-
LLA), the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE), the 
Scandinavian Simvastatin Survival Study (4S), the Heart Protection Study (HPS), the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a Study to Evaluate the 
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Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and 
Cardiovascular Events (AURORA), and Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) (29-39). 
The number of smokers and non-smokers in the statin groups of the analyzed studies was 
8,826 and 36,090, respectively. The studies started between 1988 and 2005 were multicentre 
trials. Three studies, WOSCOPS, AFCAPS/TexCAPS and JUPITER were primary prevention 
trials, the others were secondary prevention studies. The following statins were administered: 
pravastatin (4 studies), atorvastatin (2 studies), simvastatin (2 studies), rosuvastatin (2 studies) 
and lovastatin. Median follow-up varied between 1.9 and 6 years. Demographic characteristics of 
the included studies are shown in Table 1. 
 
Risk of bias assessment 
An unclear risk of bias with respect to sequence generation and allocation concealment was 
observed in some trials; but studies were low-risk in terms of other sources of bias. Table 2 
presents study quality assessment for each of the 11 RCTs included in this meta-analysis. 
 
Effect of statins on CV outcomes by smoking status 
The RR ratio for major CV events was 0.73 (95%CI: 0.67-0.81; p<0.001) in nonsmokers 
and 0.72 (95%CI: 0.64-0.81; p<0.001) in smokers (Figure 2). Moderate to high heterogeneity 
was observed both in non-smokers (I2=77.1%, p<0.001) and in smokers (I2=51.6%, p=0.024) 
groups. 
When analyzed separately, primary prevention trials showed a RR ratio for major CV events 
of 0.64 (95%CI: 0.56-0.75; p<0.001) in non-smokers and 0.58 (95% CI: 0.44-0.78; p<0.001) in 
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smokers (Figure 3). No heterogeneity was found among non-smokers (I2=0.0%, p=0.518), but it 
was moderate among smokers, but not statistically significant (I2=39.2%, p=0.193). 
Secondary prevention trials showed a RR ratio for major CV events of 0.76 (95%CI: 0.68-
0.84; p<0.001) in nonsmokers and 0.76 (95%CI: 0.67-0.86; p<0.001) in smokers (Figure 4). 
Heterogeneity was high among non-smokers (I2=80.6%, p<0.001), but it was moderate and 
insignificant among smokers (I2=46.4%, p=0.07).  
Differences in baseline risk and heterogeneity between studies are presented in l’Abbé plots 
(Figure 5). 
Smokers seem to benefit slightly more from statins than non-smokers according to the 
number needed to treat (NNT) analysis (23.5 vs 26.8) based on RRs applied to the control event 
rates. The number of avoided events per 1000 individuals was 42.5 (95%CI: 28.9-54.6) in 
smokers and 37.3 (95%CI: 27.2-46.4) in non-smokers. 
When the proportion of CV events was examined in all studies (Table 3), the placebo 
smoker was the group with the worst outcome (15.19%, 95%Cl: 14.44-15.94) with the 
comparable results for the placebo non-smoker group (14.03%; 95%Cl: 13.67-14.39), while the 
groups with the best outcomes were statin non-smokers (10.82%, 95%Cl: 10.50-11.14) and statin 
smokers (11.17%, 95%CI: 10.51-11.83). 
 
Sensitivity analysis and publication bias 
The influence of individual studies on the summary effect estimate is displayed in Figure 6 
and Figure 7. It appears that omission of any of the included studies did not significantly change 
the overall estimate. A Galbraith plot was produced to localize any trials that might cause 
heterogeneity (Figure 8). GREACE and AURORA studies are outside the pseudo 95% 
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confidence limit in non-smokers and PROSPER study is outside the pseudo 95% confidence 
limit in smokers. Harbord's modified test showed no small-study effects in either non-smokers 
(p=0.305) or smokers (p=0.072). Visual inspection of funnel plots suggested an asymmetry in 
the meta-analyses of CV outcomes both in non-smokers and smokers (Figure 9 and Figure 10).  
The OIS analysis revealed that we had sufficient data to draw the reliable conclusions. For 
each analysis the number of subjects surpassed the calculated OIS (all trials smokers OIS=4494, 
all trials non-smokers OIS=15,929; primary prevention trials smokers OIS=3538, primary 
prevention trials non-smokers OIS=4262; secondary prevention trials non-smokers OIS=13,688, 
secondary prevention trials smokers OIS 3606). 
 
DISCUSSION 
This meta-analysis did not suggest any significant difference between smokers and non-
smokers regarding the effect of statins on CV outcomes. In terms of NNTs and number of 
avoided events, the smokers seem to benefit more, although non-significantly. There was no 
suggestion of substantial difference between smokers and non-smokers analyzing the results 
from primary and secondary prevention trials, however primary prevention patients seem to 
benefit more from the statin therapy irrespective on the smoking status.  
Cigarette smoke-induced atherosclerosis involves several systemic pathways and underlying 
mechanisms (40), which are still not completely understood. Endothelial dysfunction caused by 
smoking is associated with decreased endothelial nitric oxide synthase (eNOS) expression (41-
43). The free radicals contained by cigarette smoke induce cardiac remodeling, with consecutive 
atrial fibrosis and left ventricular hypertrophy, increasing the risk of stroke (44). Furthermore, 
systemic oxygen free radicals generated by chronic smoking cause local inflammation, resulting 
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in increased serum proinflammatory cytokines, peripheral leucocytes and C reactive protein 
(CRP), promoting arterial thrombosis and increased oxidative stress (45). Compounds found in 
cigarette smoke cause structural and functional alterations in blood vessels, noticeable though 
reduced ability to contract, thickening of the intima media and arterial wall, causing myocardial 
ischemia through increased arterial stenosis in exposed smokers (46). Nicotine also stimulates 
the release of hormones from the adrenal medulla, which might alter cardiac output through 
elevating blood pressure (BP), heart rate, and ventricular contractility, leading to cardiac 
ischemia (47). Lastly, but no less importantly, one of the main forms of epigenetic modifications 
- DNA methylation, has been suggested to play an essential role in the pathways of smoking and 
diseases induced by smoking (48). A recent meta-analysis on 17 studies searching the association 
of methylation modifications in blood DNA and active smoking exposure identified three genes: 
cg03636183 (F2RL3), cg05575921 (AHRR), and cg19859270 (GPR15) as smoking-related 
genes(49), which might be used as biomarkers of smoking exposure for quantifying the risks of 
smoking-related diseases in future research studies. 
This meta-analysis might have important clinical relevance, especially as the knowledge on 
this issue has been very limited. In the GREACE study the authors investigated the impact of 
smoking on CV outcomes and comorbidities in statin-treated patients with coronary artery 
disease (CAD) (34). The authors showed that in patients on statin therapy the hazard ratio (HR) 
for current smokers compared with never smokers was 1.86 (95%CI: 1.19-2.10) with very 
similar results while comparing current smokers and ex-smokers. Absolute (16.3%) and relative 
(45.6%) risk reduction of cardiovascular disease was large in current smokers on statins in 
comparison to those not on a statin; they still had, however, the highest absolute CVD event 
incidence (19.4%) (34). Statins might effectively decrease the adverse impact of smoking with 
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their pleiotropic effects (e.g. anti-inflammatory, antioxidant and antithrombotic) (50-52) but how 
it transfers to the reduction of CVD events has been not clearly known. Agewall et al. (53) 
showed that in smokers endothelial functional flow-mediated dilation (FMD) increased 
significantly (p<0.05) on atorvastatin 80 mg and returned to basal levels during placebo. FMD 
was unaffected by either atorvastatin or placebo in the non-smoking group. The net change of 
total cholesterol or LDL-C was not associated with the net change in FMD (53). In the study by 
Januszek (54), the author assessed the impact of smoking on paraoxonase-1 (PON1) activity and 
the relationship with pleiotropic effects of simvastatin therapy and PON1 gene polymorphisms in 
patients with stable CAD and hypercholesterolemia treated with simvastatin 40 mg for 12 
months. He showed a significant decrease of hsCRP (p=0.017) and tumor necrosis factor-α 
(p=0.003) concentrations after simvastatin in smokers, and 8-iso-PGF2α in smokers and 192QQ 
allele carriers (p=0.038). In contrast to the study mentioned above, the author observed that FMD 
significantly improved only in the subgroup of non-smokers (p=0.019) and 192QQ allele carriers 
(p=0.049) (54). In a recent study, Ogawa et al. (55) analyzed the effect on statin therapy on 
malondialdehyde-modified low-density lipoprotein (MDA-LDL) level - a marker of oxidative 
stress linked to progression of arteriosclerosis. They showed that with regard to smoking status, 
MDA-LDL level was significantly higher in ex-smokers/current smokers in comparison to non-
smokers. MDA-LDL level and MDA-LDL/LDL-C ratio, in the non-statin group, were 
significantly higher in ex-smokers/current smokers compared with non-smokers, while no 
significant correlation was noted between smoking status and LDL-C level. They concluded that 
MDA-LDL level might have been affected smoking status, and statin therapy might have a 
beneficial effect on the reduction of MDA-LDL level (55). These data confirm that smoking 
significantly increases the risk of atherosclerosis progression and the patient’s overall 
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cardiovascular risk, and statins (especially at high doses) with their both potent lipid-lowering 
and pleiotropic properties might substantially reduce this risk, even slightly more than in non-
smoker patients. This is what we observed in our meta-analysis, based on the results of NNT and 
number of avoided events, as well as the RR ratios for smokers vs non-smokers in primary 
prevention trials (0.58 vs. 0.64, respectively). However, we would like to emphasize that statin 
therapy with lifestyle changes (not only smoking cessation, but also suitable diet and regular 
physical activity) is the most effective means of reducing risk of CVD, as we also observed in 
this meta-analysis (CV events ratio: 10.82% in the statin non-smoker group).   
 
Strengths and limitations of the study  
The strength of our meta-analysis is the large number of participants in RCTs. To our 
knowledge this is the first such extensive meta-analysis addressing this important issue. 
Our study has several limitations. First, we did not have access to individual patient data; 
however, taking into account the number of included subjects in this meta-analysis (n=89,604) 
the statistical power is adequate. Second, reported CV events were very heterogeneous across 
trials; we only evaluated composite CV endpoints, without insight into detailed CV events, such 
as AMI or stroke. Third, we did not have access to adjusted effects per trial, and therefore could 
not meta-analyzed adjusted effects. Fourth, the number of cigarettes smoked, duration of the 
smoking habit, or smoking cessation during follow up were not consistently reported across 
trials. Finally, there was no biochemical verification of smoking status. 
In conclusion, this meta-analysis of large randomized controlled trials suggests that the 
effect of statins on CV outcomes is similar between smokers and non-smokers, but in terms of 
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NNTs and number of avoided events, smokers seem to benefit slightly more. These findings 
should not detract from efforts to encourage smoking cessation to reduce CV risk. 
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Table 1. Demographic characteristics of the included studies. 
Study  WOSCOPS 
(29) 
CARE 
(30) 
AFCAPS/Tex
CAPS 
(31) 
LIPID 
(32) 
ASCOT-LLA 
(33) 
GREACE 
(34) 
4S 
(35) 
HPS 
(36) 
PROSPER 
(37) 
AURORA 
(38) 
JUPITER 
(39) 
Starting 
Year 
 1989 1989 1990 1990 1998 1998 1988 1994 1997 2003 2003 
Location  Scotland USA and 
Canada 
USA Australia and 
New Zealand 
Denmark, 
Finland, 
Iceland, 
Norway, 
Sweden UK, 
and Ireland,  
Greece Denmark, 
Finland, 
Iceland, 
Norway, 
Sweden 
UK Scotland, 
Ireland, and 
the 
Netherlands 
25 countries 26 countries 
Median 
follow-up 
 4.8 years 5 years 5.2 years 6 years 3.3 years 3 years 5.4 years 5 years 3.3 years 4.6 years 1.9 years 
Inclusion 
criteria 
 Men aged 45-64 
yrs. with no 
history of 
myocardial 
infarction and 
with raised 
plasma 
cholesterol 
levels (LDL-C 
of at least 155 
mg/dL, total 
cholesterol of at 
least 252 
mg/dL) 
Men and 
postmenopaus
al women if 
they had had 
an AMI 
between 3 and 
20 months 
before 
randomization
, 21 to 75 yrs. 
of age, with 
plasma total 
cholesterol 
levels of less 
than 240 
mg/dL, LDL-
C levels of 
115 to 174 
mg/dL, 
fasting 
triglyceride 
levels < 350 
mg/dL, 
fasting 
glucose levels 
< 220 mg/dL, 
LVEFs of > 
25 percent, 
and no 
Generally 
healthy 
middle-aged 
and older men 
and women 
with average 
TC and LDL-
C levels and 
with below-
average HDL-
C levels 
Patients with a 
history of 
myocardial 
infarction or 
hospitalization 
for unstable 
angina and 
initial plasma 
total 
cholesterol 
levels of 155 
to 271 mg/dL 
Men and 
women aged 
between 40 
and 79 yrs. at 
randomization
, with either 
untreated 
hypertension, 
or treated 
hypertension 
with systolic 
blood pressure 
of ≥140 mm 
Hg, diastolic 
blood pressure 
of ≥90 mm 
Hg, or both; 
total 
cholesterol 
concentrations 
of ≤6·5 
mmol/L, and 
not currently 
be taking a 
statin or a 
fibrate 
Patients 
with 
established 
coronary 
heart 
disease 
Patients with 
angina 
pectoris or 
previous AMI 
and 
cholesterol 
5.5-8.0 
mmol/L 
Men and 
women aged 
about 40–80 
yrs. with 
non-fasting 
blood total 
cholesterol 
concentratio
ns of at least 
3.5 mmol/L 
(135 mg/dL) 
were 
eligible 
provided 
they were 
considered 
to be at 
substantial 
5-year risk 
of death 
from 
coronary 
heart 
disease 
Patients 
with pre-
existing 
vascular 
disease 
(coronary, 
cerebral, or 
peripheral) 
or raised 
risk of such 
disease 
because of 
smoking, 
hypertensio
n, or 
diabetes 
Patients50 
to 80 yrs. of 
age who had 
end-stage 
renal 
disease and 
had been 
treated with 
regular 
hemodialysi
s or 
hemofiltrati
on for at 
least 3 
months 
Men ≥50 yrs. 
of age and 
women ≥60 
yrs. of age 
without a 
history of 
CVD and if, at 
the initial 
screening 
visit, they had 
an LDL 
cholesterol 
level < 130 
mg/dL and a 
high-
sensitivity C-
reactive 
protein level 
of ≥2.0 mg/L 
and a 
triglyceride 
level of < 500 
mg/dL. 
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symptomatic 
congestive 
heart failure. 
Cardiovasc
ular events 
 Non-fatal 
myocardial 
infarction and 
death from 
coronary heart 
disease 
Major 
coronary 
events were 
the primary 
end point 
(death from 
coronary heart 
disease or 
non-fatal 
myocardial 
infarction), 
coronary-
artery bypass 
grafting, or 
percutaneous 
transluminal 
coronary 
angioplasty 
Acute major 
coronary 
events defined 
as fatal or 
non-fatal 
myocardial 
infarction, 
unstable 
angina, or 
sudden 
cardiac death 
Death due to 
coronary heart 
disease and 
non-fatal AMI 
Non-fatal 
myocardial 
infarction and 
fatal coronary 
heart disease 
Cumulative 
incidence of 
major CVD 
events [all-
cause and 
CVD 
mortality, 
CVD 
morbidity 
(non-fatal 
myocardial 
infarction, 
revasculariz
ation, 
unstable 
angina, 
congestive 
heart 
failure, and 
stroke) 
Major 
coronary 
events: 
coronary 
deaths, non-
fatal definite 
or probable 
MI, silent MI 
or 
resuscitated 
cardiac arrest 
Major 
coronary 
event, 
stroke, and 
revasculariz
ation 
(defined 
prospectivel
y as “major 
vascular 
events”) 
Coronary 
heart 
disease 
death or 
non-fatal 
infarction or 
fatal or non-
fatal stroke 
Combined 
outcome 
(major 
cardiovascul
ar event), 
death from 
cardiovascul
ar causes, 
nonfatal 
myocardial 
infarction, 
and nonfatal 
stroke 
First major 
CV event, 
defined as 
nonfatal AMI, 
nonfatal 
stroke, 
hospitalization 
for unstable 
angina, an 
arterial 
revascularizati
on procedure, 
or confirmed 
death from 
CV causes 
Statin type  Pravastatin Pravastatin Lovastatin Pravastatin Atorvastatin Atorvastatin Simvastatin Simvastatin Pravastatin Rosuvastati
n 
Rosuvastatin 
Statin 
interventio
n 
 40 mg/day 40mg/day 20–40 mg/day 40 mg/day 10 mg/day 10-80 
mg/day 
20–40 
mg/day 
40 mg/day 40 mg/day 10 mg/day 20 mg/day 
Participant
s 
Statin 1445* 1855** 337* 1744** 429* 2875** 425* 4087** 1718* 3450*
* 
129
* 
751*
* 
542* 1679*
* 
144
6* 
882
3** 
753* 213
8** 
202* 118
7** 
1400* 750
1** 
Control 1460* 1832** 304* 1744** 389* 2912** 444* 4058** 1656* 3481*
* 
95* 625*
* 
596* 1627*
* 
146
7* 
880
0** 
805* 210
8** 
227* 115
7** 
1420* 748
1** 
Age (years) Statin 55±5 59±9 58±7 62 (55–67) 63±8 58±12 58±7 in men 
60±6 in 
women 
40–80 75±3 64±9 66 (60–71) 
Control 55±5 59±9 58±7 62 (55–68) 63±9 59±14 58±7 in men 
61±6 in 
women 
40–80 75±3 64±9 66 (60–71) 
Male (%) Statin 100 86 85 83 81 91* 78** 82 75 48 61 62 
Control 100 86 85 83 81 92* 75** 81 75 48 63 62 
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Values are expressed as mean ± SD or median (25 to 75 percentile);* smokers; ** non-smokers. 
Abbreviations: NS: not stated; CVD: cardiovascular disease; AMI: acute myocardial infarction; MACE: major adverse cardiac events; LDL-C: low-density lipoprotein 
cholesterol; HDL-C: high-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; WOSCOPS=West of Scotland Coronary Prevention Study; 
CARE=Cholesterol and Recurrent Events; AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study; LIPID=Long-term Intervention with 
Pravastatin in Ischaemic Disease; ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm; GREACE=The GREek Atorvastatin and 
Coronary-heart-disease Evaluation study; 4S=Scandinavian Simvastatin Survival Study; HPS=Heart Protection Study; PROSPER=PROspective Study of Pravastatin in 
the Elderly at Risk; AURORA=A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular 
Events; JUPITER=	Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin 
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Table 2. Assessment of risk of bias in the included studies using Cochrane criteria. 
 
Study Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other 
potential 
threats to 
validity 
WOSCOPS (29) U U L L L L L 
CARE (30) U U L L L L L 
AFCAPS/TexCAPS (31) U U L L L L L 
LIPID (32) U U L L L L L 
ASCOT-LLA (33) L L L L L L L 
GREACE (34) U U U L L L L 
4S (35) L L L L L L L 
HPS (36) L L L L L L L 
PROSPER (37) L L L L L L L 
AURORA (38) L L L L L L L 
JUPITER (39) L L L L L L L 
 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
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Table 3. CV outcomes among smokers and non-smokers according to treatment group. 
 
Study Group Non-smokers, % with 
CV outcomes 
Smokers, % with CV 
outcomes 
WOSCOPS (29) Statin 3.98 6.92 
Control 5.67 9.86 
CARE (30) Statin 20.01 24.03 
Control 25.05 36.84 
AFCAPS/TexCAPS (31) Statin 3.44 3.96 
Control 5.05 9.25 
LIPID (32) Statin 12.01 15.53 
Control 15.35 20.72 
ASCOT-LLA (33) Statin 1.88 2.04 
Control 2.70 3.62 
GREACE (34) Statin 10.78 19.37 
Control 24.0 35.79 
4S (35) Statin 18.11 23.43 
Control 26.37 32.38 
HPS (36) Statin 19.31 22.75 
Control 24.64 28.36 
PROSPER (37) Statin 13.70 15.27 
Control 16.51 15.53 
AURORA (38) Statin 28.39 29.21 
Control 29.04 31.72 
JUPITER (39) Statin 1.47 2.28 
Control 2.53 4.37 
*Abbreviations explanations of all RCTs have been presented in the text of the manuscript.   
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FIGURE LEGENDS:  
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis. 
Figure 2. Forest plot displaying RR and 95% confidence intervals for the impact of statin on 
cardiovascular outcomes in smokers and non-smokers. Squares represent the point of estimate of 
each study; square size corresponds to the weight of the study in the meta-analysis. Horizontal 
lines denote the respective 95% CIs. The diamond represents the overall pooled estimate of statin 
effect. 
Figure 3. Forest plot displaying RR and 95% confidence intervals for the impact of statin on 
cardiovascular outcomes in smokers and non-smokers in primary prevention trials. Squares 
represent the point of estimate of each study; square size corresponds to the weight of the study 
in the meta-analysis. Horizontal lines denote the respective 95% CIs. The diamond represents the 
overall pooled estimate of statin effect. 
Figure 4. Forest plot displaying RR and 95% confidence intervals for the impact of statin on 
cardiovascular outcomes in smokers and non-smokers in secondary prevention trials. Squares 
represent the point of estimate of each study; square size corresponds to the weight of the study 
in the meta-analysis. Horizontal lines denote the respective 95% CIs. The diamond represents the 
overall pooled estimate of statin effect. 
Figure 5. L’Abbé plot of control group risk (x-axis) against treatment group risk (y-axis) in non-
smokers and smokers. Each circle denotes a study included in the meta-analysis. Circle size 
corresponds to the weight of the study in the meta-analysis. 
Figure 6. Results of an influence analysis in which the meta-analysis is re-estimated after 
omitting each study in smokers. 
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Figure 7. Results of an influence analysis in which the meta-analysis is re-estimated after 
omitting each study in non-smokers. 
Figure 8. Galbraith plot. The ratio of the RR log of cardiovascular outcomes divided by its 
standard error versus the reciprocal of the standard errors in non-smokers and smokers. Includes 
confidence intervals around the fixed effect summary effect line. 
Figure 9. Funnel plot for assessment of publication bias in the model of comparison the RRs of 
the association between statin users vs. controls and cardiovascular outcomes in smokers. Each 
circle denotes a study included in the meta-analysis. The dashed vertical line represents the 
overall effect calculated with the random-effects model. 
Figure 10. Funnel plot for assessment of publication bias in the model of comparison the RRs of 
the association between statin users vs. controls and cardiovascular outcomes in non-smokers. 
Each circle denotes a study included in the meta-analysis. The dashed vertical line represents the 
overall effect calculated with the random-effects model. 
 
 
 
 
 
 
 
 
 
